Je kan vanaf nu Afl. 12: MRI & AI bekijken en/of beluisteren op Youtube. Is er een verschil tussen #scanners ? Waarom moet je altijd onder dezelfde scanner gaan? .Wat kan #ai hierin betekenen? Wordt een radioloog dan overbodig?.@4nnsMiles .

Best wishes for a wonderful 2025!.May peace, love, good health and joy be your constant companions #happynewyear

Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.

What a big legacy, what a great researcher, what a great teacher, what a great visionary, what a great man… a true example and inspiration. We will miss you dearly. RIP 😔.

RT @ECTRIMS: Professor Giancarlo Comi stressed the importance of listening to individuals with MS, pointing out that their experiences are….

Ook voor #ectrims2024 Dag 3 overloop en verduidelijk ik kort de belangrijkste topics (met een mooie afsluiter) in een korte video.

De highlights van #ectrims2024 Dag 2.

RT @drbarrysinger: Lebrun-Frenay: Preventive healthcare in multiple sclerosis will need to focus on lifestyle and Epstein-Barr vaccination.….

Low anti-inflammatory effect of tolebrutinib but clear effect on disease progression… but many analysis are pending: why no effect on brain atrophy/why is the effect Gd+ lesions low/….Hopefully deep dive in the data will learn us more! 🤞🏻…let’s get on this 💪🏻.

Fox Rob (US): tolebrutinib vs placebo in nrSPMS (HERCULES trial).- 6m CDP: 31% decreases risk on tolebr.- 3m CDP: 24% “.- 6m CDI: increased chance on tolebr.- brain atrophy: no difference 🤔.Hopes are up for a change for persons with SPMS 🤞🏻👏🏻💪🏻.#ECTRIMS2024

Jiwon Oh (US): tolebrutinib vs teriflunimode in RRMS (GEMINI trials). - ARR : no difference!.- 6m CDW: 29% reduction on tolebr.- 3m CDW: 27% reduction on tolebr.- New Gd+ lesions are higher on tolebrutinib!.- T2 lesions: no difference .- good safety profile.#ECTRIMS2024

Chataway (UK): MS-stat2 study on simvastatin 80mg vs placebo in SPMS. Large phase 3 trial, unfortunately no significant effect on confirmed progression 🤷🏻‍♂️.#ECTRIMS2024

Kowalec (US) effect of genetic predisposition for depression on disease activity in #MS. Higher risk of relapse and EDSS progression in persons with higher predisposition for depression! .Importance of comorbidity on MS disease course!.#ECTRIMS2024

Abdelhak: effect of fingolimod and anti-CD20 treatment on sGFAP (z-scores) evolution & subsequent effect on PIRA in RRMS pts. Lowering Z-GFAP in first two years of treatment decreases PIRA risk in subsequent years by 44 (aCD20)-55%(fingo) sNFL does not add effect.#ECTRIMS2024

1. Unfortunately ‘measuring’ B cell tolerance defects is cumbersome and not readily available for the clinic 🤷🏻‍♂️.2. Extending the interval of course has also other goals: decreasing infections risk (and treatment costs) f.e.

Nourbakhsh (US): prospective study on anti-CD20 ‘induction’ in RRMS:.6 months treatment only. 19 pts study…but nice results. Risk of reoccurrence of disease is higher in patients with central tolerance defect @baseline! B-cell return ‘as such’ is not predictive. #ECTRIMS2024

1. Per patient, the interval seems to be quite stable (f.e. 10months every time before repopulation in same patient).2. Cutoff used for repopulation was 10cells/ml (0,01/mcl) abs count!.

Hogenboom (NL): first results of BLOOMS trial: standard vs extended interval dosing of ocrelizumab based on B-cell counts. No difference in efficacy (Relapses and MRI lesions)! .(Long term results to follow).Big difference in intervals are seen (see slide).#ECTRIMS2024

RT @bollo_luca: Excited to have just presented at #ECTRIMS2024 our work showing that thalamic atrophy at baseline predicts PIRA in early-MS….

Müller Jannis: MSBase register study in de-escalation of treatment in #MS. Increased risk of relapse reoccurring remains 2.3x higher. No real cutoff for age, EDDS, disease duration or time from last relapse was found. Note: Most were on natalizumab in this study!.#ECTRIMS2024

Monitoring is not easy: no real biomarker to predict 🤷🏻‍♂️.#ECTRIMS2024

Bruijstens (NL): de-escalation (=reducing, not stopping) treatment in NMOSD/MOGAD. Relapse risk decreases in MOGAD over time, but not in NMOSD (AQP4+). No real good option in the latter: relapse risk remains 9-38% (after stopping R/ 82%!!).No good data on MOGAD. #ECTRIMS2024.